US 11,655,257 B2
MK2 inhibitors, synthesis thereof, and intermediates thereto
Gregg Brian Feigelson, Chester, NY (US); Maryll E. Geherty, Pennington, NJ (US); Richard Martin Heid, Jr., Maplewood, NJ (US); Mohit Kothare, Bridgewater, NJ (US); Hon-Wah Man, Princeton, NJ (US); Alexander L. Ruchelman, Cream Ridge, NJ (US); John F. Traverse, Lebanon, NJ (US); Kelvin Hin-Yeong Yong, Westfield, NJ (US); and Chengmin Zhang, Florham Park, NJ (US)
Assigned to Celgene CAR LLC, Pembroke (BM)
Filed by Celgene CAR LLC, Pembroke (BM)
Filed on Jan. 14, 2021, as Appl. No. 17/148,903.
Application 17/148,903 is a division of application No. 16/494,701, granted, now 10,894,796, previously published as PCT/US2018/022547, filed on Mar. 15, 2018.
Claims priority of provisional application 62/472,024, filed on Mar. 16, 2017.
Prior Publication US 2021/0139501 A1, May 13, 2021
Int. Cl. C07D 215/02 (2006.01); C07D 215/18 (2006.01); C07D 495/04 (2006.01); C07D 495/14 (2006.01)
CPC C07D 495/14 (2013.01) 10 Claims
 
1. A compound selected from the group consisting of:

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
or a salt thereof.